AMPLIFY-EXT Puts Eliquis In Position For A New VTE Indication
This article was originally published in Pharmaceutical Approvals Monthly
The long-term prevention trial had a unique design in that it tested two different doses of Bristol/Pfizer’s anticoagulant apixaban. Both doses demonstrated an 80% reduction in events compared to placebo, but without an increase in major bleeding – reinforcing Eliquis’ strong safety profile.
You may also be interested in...
Bristol and Pfizer expect to launch novel anticoagulant Eliquis within weeks in Germany and the U.K. following approval in Europe on Nov. 20. Eliquis looks well-positioned to compete in Europe with a label reflecting superiority on safety, efficacy for stroke prevention and mortality.
With positive data now in for Xarelto’s ability to treat and prevention recurrence of VTE, Janssen looks to file for a fourth indication for the novel anticoagulant, positioning the drug to crack a promising market that may be under-appreciated.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.